文献速递贫血与红细胞疾病

利用电子健康记录数据在大型基因分型队列中准确识别镰状细胞病病例

Accurate identification of sickle cell disease cases in a large genotyped cohort using electronic health record data.
PubMed 文献 · Blood Adv · 2026-01-01

结果显示算法灵敏度97.6%、特异度99.9%、阳性预测值98.9%、阴性预测值99.9%,并可区分HbSS/HbSβ0、HbSC和HbSβ+三种表型。

要点

  • 更新版EHR算法识别SCD的灵敏度和特异度均超过95%。
  • 算法对HbSS/HbSβ0灵敏度最高(96.8%),HbSβ+较低(85%)。
  • 该算法可支持基因治疗后同期对照队列的构建。

核心结论

  • 基于ICD和实验室数据的更新版VUMC算法能在大型医疗系统中准确识别SCD个体,并区分HbSS/HbSβ0、HbSC和HbSβ+三种表型。

研究设计与样本

  • 以基因测序结果为参考标准,评估EHR算法的灵敏度和特异度等指标。

主要发现

  • 三种SCD表型占队列个体的98.5%。
  • 算法对HbSS/HbSβ0灵敏度为96.8%(272/281),对HbSC为93.7%(136/145),对HbSβ+为85%(34/40)。
  • 算法对三种表型的特异度均为99.9%。

关键数值与推荐

  • HbSS/HbSβ0灵敏度96.8%(272/281),HbSC灵敏度93.7%(136/145),HbSβ+灵敏度85%(34/40),三种表型特异度均为99.9%。

临床怎么用

  • 该算法可用于在电子健康记录中准确识别SCD患者,支持构建基因治疗的同期对照队列。
  • 算法可区分HbSS/HbSβ0、HbSC和HbSβ+表型,有助于表型特异性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The US Food and Drug Administration recently approved sickle cell disease (SCD) gene therapies that require a contemporaneous cohort to compare their outcomes with those of individuals who did not receive gene therapy. Previously, we developed an automated algorithm to create a contemporaneous cohort of children and adults with SCD using electronic health record data. We tested the hypothesis that the updated Vanderbilt University Medical Center (VUMC) algorithm can identify individuals with SCD with sensitivity and specificity of >95%. In the VUMC health care system, we identified a cohort of 33 141 adults and children of primarily African ancestry who underwent β-globin gene sequencing, with a 1.4% prevalence of SCD (473/33 141). For SCD, the performance of the VUMC algorithm using International Classification of Diseases (ICD) and laboratory data showed a sensitivity of 97.6% (462/473), specificity of 99.9% (32 663/32 668), positive predictive value of 98.9% (462/467), and negative predictive value of 99.9% (32 663/32 674). Three SCD phenotypes account for 98.5% of the individuals in the cohort. The cohort had sensitivities of 96.8% (272/281), 93.7% (136/145), and 85% (34/40) for hemoglobin SS (HbSS)/Hb Sβ0-thalassemia (HbSβ0), HbSC, and HbSβ+, respectively. The cohort had a specificity of 99.9% across all 3 phenotypes: HbSS/HbSβ0, HbSC, and HbSβ+, respectively. We have developed an updated algorithm using ICD and laboratory data that accurately identifies individuals with SCD within a large health care system, and distinguishes HbSS/HbSβ0, HbSC, and HbSβ+.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wuichet K, Corty R, Bick A, et al. Accurate identification of sickle cell disease cases in a large genotyped cohort using electronic health record data. Blood Adv. 2026. PMID: 41921205. doi:10.1182/bloodadvances.2025018414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。